CFTC clears stock perpetuals under Rule 40.3 as Cboe challenges approval

What Regulation 40.3 approval actually covers

Selig's statement calls the products Equity Perps and says they were deemed approved as security futures products under the Commodity Futures Modernization Act of 2000. He says the contracts remain subject to applicable commodity law, federal securities laws and both agencies' regulatory frameworks. The statement describes an approval within a legal category; it does not announce that every platform with a US customer base can offer the instruments. The regulator's explanation.

The exchange qualification is in the statement's first footnote. Its reference to CFTC-registered exchanges means designated contract markets also registered with the SEC as notice-registered national securities exchanges for security futures products. Retain that full description when comparing a news headline with a provider's legal documents. Shortening it to “CFTC exchange” loses the additional securities-registration condition that the statement expressly supplies.

Cointelegraph independently reports the approval and says Selig did not identify the exchanges that would offer the contracts or give a trading-start timetable. It describes perpetual futures as exposure to an asset's price without ownership of the underlying or an expiration date. That distinction is relevant for someone comparing a stock purchase with a derivative carrying the same company's name. Cointelegraph's report.

For the reader, the sequence is therefore product identification, provider identification, then account access. An issuer name or ticker answers only part of the first question. A regulator's description of the legal route cannot supply the missing product specification, a particular account's permission or the price at which an order could execute. Those need evidence attached to the intended contract.

Cboe's challenge changes the questions to ask

Cboe's November 3 statement says it joined action brought by the Capital Markets Alliance against the CFTC's approval of perpetual derivatives on US stocks and ETFs. It identifies Cboe, Citadel Securities and Healthy Markets Association as members of the alliance. Cboe argues that securities products belong on registered securities platforms with the protections required by securities law. That is the challenger's position, not a court finding. Cboe's statement distributed through PR Newswire.

The release also says the action requests injunctive relief. A request for an injunction and an injunction granted by a court are different events. The opened statement establishes the request. It supplies no basis for writing that trading has already been stopped, that approval has been overturned or that an existing customer's position must close.

The documents also describe their subject with slightly different breadth. Selig's statement specifically discusses individual equity securities. Cboe's release refers to US stocks and ETFs. Keep each description attached to its source. Neither wording gives us a verified roster of tradable instruments, and combining them does not produce one.

Our interpretation is that two records now matter for a prospective user: the contract's operating documents and dated updates on the challenge. A general argument about jurisdiction does not tell a reader how an individual platform will handle an order. Conversely, a visible product screen would not resolve the legal dispute. Check for a concrete notice affecting the product rather than assigning operational consequences to the mere existence of litigation.

Separate the contract from the shares

Cointelegraph's description makes one distinction explicit: a perpetual future provides price exposure without ownership of the underlying asset. A reader who wants a company share should check the legal description of what would appear in the account. The same ticker in two interfaces is not enough to establish the same entitlement. Our comparison of tokenized shares and stock perpetuals provides a separate starting point for that question.

Write down the full product name before comparing costs. Then inspect its reference asset, settlement terms and any explanation of the holder's rights. Treat an unanswered field as a question for that specific provider. Do not fill it with the rules of a crypto perpetual you already trade, or assume that a familiar stock symbol establishes a direct holding of the company.

The same discipline applies to the word “perpetual.” The absence of an expiration date in the report does not tell us the funding schedule, collateral policy, trading hours or position controls of an approved stock contract. We have not verified those specifications for a named offering in this run. They should come from the contract being considered, rather than from an analogy to a different market.

Our stock-linked products hub can help frame a comparison between product types. Use the contract documents to complete it. The regulatory news is relevant context for that comparison; it is not evidence that a tokenized share and an equity perpetual represent interchangeable claims.

Four checks before changing an account or an order

1. Identify the contracting entity. Open the legal information attached to the intended product and record the provider's full name. Compare its stated exchange status with the dual-registration category in Selig's statement. If the names or registrations do not match, resolve the difference before treating the regulator's announcement as evidence about that account.

2. Read the contract specification. Record the exact underlying, settlement asset, trading schedule and any displayed margin or funding terms. These are questions to answer, not terms established by today's approval. Keep the document date with the record so that a later change can be compared with the version you actually read.

3. Check access inside the relevant account. Look for the product permission and the entity serving that account. A news report mentioning a platform brand does not verify access for every country or customer. This article has not established a fee schedule, leverage limit, minimum order or account-level opening date for any named venue.

4. Review existing exposure separately from a possible new trade. Match each open position and outstanding order to its own full symbol and provider. Read any product-specific notice before changing it. Neither source establishes that positions on another venue have been migrated, prohibited or automatically converted because of this approval or challenge.

For readers already using Coinbase or another named platform, those checks should begin in the existing account's product documents. Cointelegraph says Coinbase, Kalshi and Bitnomial were among the earlier applicants; that historical filing detail does not establish which offering is live now. Do not send funds to a new route simply because a report contains the brand you recognize.

The useful comparison is a record you can repeat: entity, contract name, permissions and terms. It lets you distinguish a new legal possibility from a product you can actually evaluate. It also leaves a clear question when the information is missing, such as whether the product belongs to the same entity that holds an existing balance.

What a later update would need to establish

A trading-start update should identify the exchange, contract and start time. An access update should identify the account population or relevant restrictions. A litigation update should distinguish a party's request from a court order and state the order's scope. Those are different kinds of evidence; one should not stand in for another.

The CFTC statement supplies the approval route and its regulatory category. Cboe supplies its opposition and request for relief. Cointelegraph confirms the development while noting the missing exchange roster and timetable. None of those opened sources supplies a synchronized quote, trading volume or measured share-price response attributable to the decision. We therefore draw no conclusion about a market move or its cause.

The first-report lead in this slot dates to November 3 at 22:05 SGT. Read later operational notices with their own timestamps, rather than treating a refreshed headline as a new launch event. For a reader following several stock-related products, keep the product-type comparison beside the actual specification and update only the fields supported by a dated notice.

Quick answers

Does approval mean I own the stock?

No. Cointelegraph describes perpetual futures as price exposure without ownership of the underlying. Check the legal rights of the exact product before comparing it with a share purchase. A company name in the contract title does not establish shareholder rights.

Has Cboe already stopped the contracts?

The opened Cboe statement says the action seeks injunctive relief. It does not announce that the court granted that relief. A report of a filed request cannot establish a trading halt or the treatment of existing orders.

Can I assume the product is available in my account?

No. The regulator describes qualifying exchanges, and Cointelegraph says Selig supplied neither a venue list nor an opening timetable. Start with the entity and permissions shown for the actual account, then obtain the contract's dated terms before comparing a proposed order with an existing holding.